Conformationally restrained de novo peptides to modulate Skp1-Skp2 interaction of the SCF E3 ligase.
De novo peptide sequences are introduced through in silico screening of a peptide pool to target the Skp1-Skp2 core interface and establish the potential of first-in-class peptides in targeting the Skp1-Skp2 interface for the treatment of cancers driven by Skp2.